Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars

Phase 2

Completed

• Conditions: Acne Scars
• Interventions: Drug: Adapalene

• Registration Number: NCT01213199
• Lead Sponsor: Galderma R&D

Brief Summary

The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-09-30
• Study First Submitted QC: 2010-09-30
• Study First Posted: 2010-10-01
• Study Start: 2011-03
• Primary Completion: 2012-04
• Study Completion: 2012-09
• Results First Submitted: 2013-11-22
• Status Verified: 2015-03
• Results First Submitted QC: 2015-03-09
• Results First Posted: 2015-03-23
• Last Update Submitted: 2021-02-16
• Last Update Posted: 2021-02-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Male or female subjects of any race, aged 18 to 50 years inclusive
• Subjects with a past history of acne and with moderate to severe facial atrophic acne scars

Exclusion Criteria

• Subjects with active inflammatory acne lesions
• Subjects with hypertrophic acne scars

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Differin 0.3%	Adapalene	Differin® 0.3% Gel Adapalene 0.3% Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks.

Primary Outcome Measures

Name	Time	Method
Global Scarring Severity	Week 24	Grade Level: 1. Macular disease; 2. Mild disease; 3. Moderate disease; 4. Severe disease

Trial Locations

Locations (1)

Manisha PATEL; 🇺🇸 Baltimore, Maryland, United States